Novel de novo EEF1A2 missense mutations causing epilepsy and intellectual disability

Citation for published version:

Digital Object Identifier (DOI):
10.1002/mgg3.219

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published in:
Molecular Genetics & Genomic Medicine

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Novel de novo EEF1A2 missense mutations causing epilepsy and intellectual disability


South East of Scotland Clinical Genetics Service, Crewe Road, Edinburgh, UK
Centre for Genomic & Experimental Medicine, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK
Muir Maxwell Epilepsy Centre, University of Edinburgh, 20 Sylvan Place, Edinburgh EH9 1UW, UK
Paediatric Neurosciences, Royal Hospital for Sick Children, Sciennes Road, Edinburgh EH9 1LF, UK
Epilepsy Center, Departments of Pediatrics and Neurology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Northwestern University
Feinberg School of Medicine, 225 E Chicago Ave, Box #29, Chicago, Illinois 60611
MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK
Child Life and Health, University of Edinburgh, 20 Sylvan Place, Edinburgh EH9 1UW, UK
South West Thames Regional Genetics Service, St George’s Hospital, Tooting, London, UK
Division of Medical Genetics, Arkansas Children’s Hospital, Little Rock, Arkansas
DDD Study, Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK

Keywords
Autism, EEF1A2, epilepsy, intellectual disability, translation elongation

Correspondence
Catherine M. Abbott, Centre for Genomic & Experimental Medicine, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK. Tel: +441316518745; Fax: +441316518800; E-mail: C.Abbott@ed.ac.uk

Funding Information
Wellcome Trust (Grant/Award Number: WT098051).

Received: 18 December 2015; Revised: 12 February 2016; Accepted: 16 February 2016

doi: 10.1002/mgg3.219

Abstract

Background
Exome sequencing has led to the discovery of mutations in novel causative genes for epilepsy. One such gene is EEF1A2, encoding a neuromuscular specific translation elongation factor, which has been found to be mutated de novo in five cases of severe epilepsy. We now report on a further seven cases, each with a different mutation, of which five are newly described.

Methods
New cases were identified and sequenced through the Deciphering Developmental Disabilities project, via direct contact with neurologists or geneticists, or recruited via our website.

Results
All the mutations cause epilepsy and intellectual disability, but with a much wider range of severity than previously identified. All new cases share specific subtle facial dysmorphic features. Each mutation occurs at an evolutionarily highly conserved amino acid position indicating strong structural or functional selective pressure.

Conclusions
EEF1A2 should be considered as a causative gene not only in cases of epileptic encephalopathy but also in children with less severe epilepsy and intellectual disability. The emergence of a possible discernible phenotype, a broad nasal bridge, tented upper lip, everted lower lip and downturned corners of the mouth may help in identifying patients with mutations in EEF1A2.
Introduction

The advent of family based exome sequencing has facilitated the discovery of de novo and/or inherited ultrarare mutations in an increasingly large number of genes as the cause of epilepsy. Some of these genes have quite unexpected cellular functions. In these cases, the burden of proof that the mutations are causative rests not just on the fact that they have occurred de novo, and the absence of such mutations in unaffected individuals, but also on the predicted effects on the protein, and whether more than one mutation is found in the same gene (or the same mutation is found in multiple affected individuals).

One gene in which missense mutations have recently been reported is EEF1A2, encoding translation elongation factor 1A2 (OMIM #602959). Elongation factor eEF1A has a key role in protein synthesis, the delivery of aminoacylated tRNAs to the ribosome. In addition to this role, eEF1A has been reported to have numerous noncanonical "moonlighting" properties, possibly by virtue of its abundance in the cell, where it comprises 3% of the total protein (Condeelis 1995).

While mutations affecting such a basic housekeeping function would at first glance seem unlikely to affect only neurodevelopment, the specificity of the disorder is determined by the expression pattern of eEF1A isoforms. All vertebrates have two independently encoded isoforms of eEF1A; eEF1A1 is ubiquitously expressed throughout development but is then switched off specifically in neurons and muscle postnatally, where it is replaced by eEF1A2 (Chambers et al. 1998; Khalyfa et al. 2003). eEF1A2 is unique among translation factors in being tissue-specific. It is expressed only in neurons and muscle, with minor specific sites of expression in pancreatic islet cells and enteroendocrine cells. Complete loss of function of eEF1A2 in the mouse (via a homozygous deletion of the promoter and first exon) causes severe neurodegeneration, loss of muscle bulk and death by 4 weeks (Chambers et al. 1998). Mice that are heterozygous for this loss of function mutation, on the other hand, have no gross motor problems even at 21 months (Griffiths et al. 2012).

In humans, three distinct missense mutations in EEF1A2 have been reported in five patients. The initial report was in a study of individuals with severe intellectual disability (ID): a Gly70Ser mutation was found in a female with severe ID, autistic features and aggressive behaviors. She was also reported to have myoclonic, absence, and grand mal seizures (de Ligt et al. 2012). The second report was in a survey of children with epileptic encephalopathy, where the same Gly70Ser mutation was identified in a 14-year-old boy with refractory epilepsy. He also has limited comprehension and is nonverbal (Veeramah et al. 2013). A third Gly70Ser mutation was reported in a 1-year-old girl, but no clinical information was included beyond a broad categorization as "neurological with other systems involvement" (Yang et al. 2014). The fourth and fifth individuals were identified in Japan; both have autism and severe ID. One had infantile spasms, now controlled by valproate, the other has generalized tonic seizures. In addition, both girls were said to have characteristic facial features. They each have different missense mutations, Glu122Lys and Asp252His, respectively (Nakajima et al. 2015). Two further cases of Glu122Lys mutations have recently been described (Inui et al. 2015).

We now report the finding of further mutations, all of which have arisen de novo on one allele in the affected individuals. We report on seven cases, each with a different mutation, of which five are newly described. All are associated with epilepsy and ID, but with a much wider range of severity than previously suspected. We note characteristic facial features in all patients for whom we could obtain photos.

Methods

Ethical compliance

This study has UK Research Ethics Committee approval (10/H0305/83, granted by the Cambridge South REC, and GEN/284/12 granted by the Republic of Ireland REC).

Recruitment

Patients were recruited through personal communication with clinicians, via a website (http://eeff1a2epilepsy.wordpress.com/) and from the Deciphering Developmental Disorders (DDD) project (http://www.ddduk.org/). A pro forma was designed and sent to clinicians; where possible this was used in conjunction with the information deposited in DDD.

Sequencing and analysis

Trio-based exome sequencing was performed as part of the DDD study as previously described (Deciphering Developmental Disorders 2015; Wright et al. 2015). In brief, target capture using Agilent SureSelect 55 MB Exome Plus was performed on saliva- or blood-derived genomic DNA from each affected individual and their parents and sequenced on Illumina HiSeq. DeNovoGear21 was used to identify de novo sequence variants and Ensembl Variant Effect Predictor (VEP version 2.6, http://www.ensembl.org/info/docs/tools/vep/index.html) was used to predict the effect of each genomic variant. PolyPhen-2 analysis was carried out at http://genet
heterozygous constitutive c.208G- 

dysmorphisms were noted. She was found to have a

was 46.5 cm at 9 months (91st centile) but no particular

history on the mother’s side, and her head circumference

hemangioma on her left temple, for which there is a family

 anomalies. She is unable to walk. She has a small

motor milestones; she only sat from 14 months. Seizure

onset was at age 2 years, sometime after her developmental

delay was first noted. The seizures were characterized

by head drops which then evolved to eye rolling and arm

extension occurring in clusters reminiscent of infantile

spasms. She has continued to have seizures which have

been resistant to medication. Head circumference mea-

sured at age 8.75 years was 51.5 cm (<50th centile). She is

still unable to walk independently and has no speech. She

has brachycephaly with small wide-spaced teeth. She is
generally hypotonic and has cold peripheries. She now has

reduced bone density with fractures and thoracolumbar

scoliosis. She was found to have a heterozygous de novo

constitutive c.271G->A (p.D91N) mutation in EEF1A2.

Case 4

Case 4 is a 9-year-old girl who was born weighing 3.86 kg

(>75th centile). She had focal seizures as an infant but now

has myoclonic, tonic, and occasional tonic-clonic seizures,

occurring daily. She has severe hypotonia and severe global

delays. She has no head control, no ability to grasp objects,
is nonverbal and unable to sit or bear weight on legs. She

has very poor bone density. Her head circumference was

43.6 cm at 6 months (<75th centile), and 50 cm at 6 years

(>2nd). She was found to have a heterozygous de novo

c.292T>C (p.F98L) mutation in EEF1A2.

Case 5

Case 5 is a 6-year-old girl born after a normal pregnancy

at 41 weeks, weighing 3.43 kg (50th centile). Hypotonia

was noted during the neonatal period with subsequent

gross motor delay. She sat unsupported at 15 months and

walked independently from 4 years. She has no speech

but vocalizes and uses signs. Seizures developed at

10 weeks as jerky, stiffening of legs several times a week,

which then developed to include head nodding. Her

symptoms improved on commencement of sodium val-

proate. An initial EEG at 10 months was normal but

showed spikes and polyspikes with some slow wave activ-

ity at 21 months. She was described to have downslanting

and slightly short palpebral fissures, a broad forehead and

a broad, flat nasal bridge with downturned corners of the

mouth and head circumference below the 2nd centile. She

was found to have a heterozygous de novo constitutive

c364G->A (p.E122K) mutation in EEF1A2.

Case 6

Ten-year-old girl born at 40 weeks by planned Cesarean

section weighing 3.69 kg (<75th centile). Initial gross and

fine motor development was normal but only walked
independently at 2 years. No evidence of hypotonia. Speaks in sentences, with significant delays in language and comprehension but pleasant and friendly; in mainstream primary but will go to special school at secondary level. Gait and coordination immature but essentially normal. Seizures commenced at 3 months, and were initially myoclonic seizures. She then developed absence seizures at the age of 2 years which are now controlled by valproate and lamotrigine. EEG shows slow background rhythms and generalized epileptic discharges. Her MRI brain is normal. Head circumference 51 cm at 5.2 years (25th centile). Broad base nose, prominent midface and thin upper lip but normal eyes. Found to have heterozygous de novo constitutive c.370G>A (p.E124K) mutation in EEF1A2.

Case 7

Case 7 is a 5-year-old boy born at 41 weeks by Cesarean section for decreased fetal heart rate weighing 2.80 kg (9th centile) following an uncomplicated pregnancy. Family history negative for seizures or developmental concerns in either parent, but the boy has a maternal uncle with developmental delays who is able to live independently. Developmental history notable for sitting with support at 18 months and currently he does not walk, has no speech, and is able to help feed himself. Past medical history significant for food allergies, eosinophilic esophagitis, and pancreatitis. He is frequently irritable and uncomfortable – he cries and grinds his teeth, kicking his legs and flapping his hands. He has choreic movements and disturbed sleep which responds partially to melatonin. His first seizure was at 4 months and was characterized by rightward eye deviation and right limb motor activity. Initial EEG was abnormal and brain MRI abnormal due to mild hypoplasia of corpus callosum and mild global volume loss (that is progressive on subsequent MR neuroimaging). He started phenobarbital and had no further seizures until 6 months old when he developed infantile spasms. Despite multiple rounds of ACTH/steroids and multiple anticonvulsant trials he continues to have seizures of multiple types including isolated epileptic spasms, myoclonic, myoclonic-tonic, tonic, and tonic-clonic seizures. His head circumference was 50 cm at 5 years (>25th centile). This boy was found to have a heterozygous de novo c.1267 C>T (p.R423C) mutation in EEF1A2. The clinical findings are summarized, together with those in previous reports, in Table 1.

All the mutations are missense, and have arisen de novo. Each of the individuals identified as having a mutation in EEF1A2 has experienced repeated seizures, and in some cases they now have intractable epilepsy. Almost all show global developmental delay and hypotonia, but one individual, case 6, is clearly much less severely affected than the others. She has much milder but still moderate ID, and has had no seizures for a number of years.

In contrast to the previously published cases, none of the individuals we report has been diagnosed with autism. Head circumference is frequently, but not invariably, affected, but in the absence of longitudinal data it is hard to know whether this could be associated with specific mutations, or whether it varies with age. Gait abnormalities have been reported in the two individuals with E122K mutations, and one of the children with a G70S mutation. It is impossible to tell whether this would be consistently associated with mutations in EEF1A2, or only with specific mutations, as many of the patients are unable to walk. Other individuals have previously undescribed features like food allergies and reduced bone density.

Apart from case 2, we were able to obtain photographs of all the children reported here (Fig. 1). We examined these, along with reports from their clinicians, to establish whether the features reported in the two girls described by Nakajima et al. (2015) were seen consistently, to establish a possible dysmorphic phenotype for patients with EEF1A2 mutations. The features which were common in the original two patients were deep set eyes, epicanthus, depressed nasal bridge, tented upper lips with high arch palate and an everted lower lip. Of our seven patients only three had any remarks with regards to possible dysmorphisms and there were no commonalities among the descriptions. However, on examination of the photographs it is possible to see certain distinct features emerging. Table 2 shows a summary of the facial features seen in our patients together with those described in Nakajima et al. (2015). The epicanthus and depressed nasal bridge described by Nakajima et al. (2015) are most likely due to ethnic origins, since these are not seen or described in our patients except in case 3 and case 5, respectively. A more common finding is a broad nasal bridge. The lower facial features were more consistent with 5/6 of our patients displaying a tented upper lip and eversion of their lower lip, associated with downturned corners of mouth. This is clearly demonstrated in cases 1, 3, and 5 and more subtly in cases 4 and 7 (Fig. 1). None of our patients were reported to have abnormal palates. Additional features which may be of significance are full cheeks, which have been mentioned by Nakajima et al. (2015), and large ears, but these are difficult to fully quantify given the modest numbers of cases and absence of detailed measurements.

Predicted effects of the mutations on the protein

All the known mutations are missense, changing a single, highly conserved, amino acid. Table 3 lists all changes found at the DNA and protein level, together with the
predicted effect of each amino acid substitution on the eEF1A2 protein.

Each of these mutations is strikingly conserved throughout evolution. Although the specific EEF1A2 isoform seen in neurons is not found in species lower than vertebrates, genes encoding EF1alpha are seen in all life forms. If we use all isoforms for comparison, therefore, the amino acids that are mutated in five cases are strictly conserved throughout evolution to E.coli, and the remaining three are conserved in yeast (S. cerevisiae, Fig. 2). This dramatic level of conservation clearly suggests strong selective pressure and functional consequences of mutating any one of these amino acids.

### Table 1. Summary of phenotypic characteristics seen in each case with a missense mutation in EEF1A2.

<table>
<thead>
<tr>
<th>Protein change</th>
<th>Epilepsy</th>
<th>Autism</th>
<th>SID/delay/motor delay</th>
<th>Hypotonia noted</th>
<th>Other</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gly70Ser</td>
<td>Myoclonic seizures, grand mal, absences</td>
<td>Yes</td>
<td>Global developmental delay, SID</td>
<td>Yes</td>
<td>No</td>
<td>Normal head circumference at 22 years</td>
</tr>
<tr>
<td>Gly70Ser</td>
<td>Infantile spasms, then myoclonic, refractory</td>
<td>NR</td>
<td>Non-verbal</td>
<td>Yes</td>
<td>NR</td>
<td>Acquired microcephaly &lt;2nd centile, gait instability</td>
</tr>
</tbody>
</table>
| Gly70Ser       | Epileptic encephalopathy | NR | Global developmental delay | Yes | Yes | No microcephaly at 9 months, dysphagia | Yang et al. 2014
| Ile71Leu       | Seizures | NR | Global developmental delay | NR | Yes | Head circumference >9th centile, brachycephaly | This study, case 2 |
| Asp91Asn       | Head drops, then infantile spasms. Continued head drops and atypical absences | NR | Global developmental delay | Yes | Yes | Head circumference <50th centile. Brachycephaly. Reduced bone density with fractures | This study, case 3 |
| Phe98Leu       | Focal seizures as infant, now myoclonic, tonic and occasional tonic-clonic | No | Global developmental delay | Yes | Yes | Head circumference 85th centile at 6 months, Reduced bone density. | This study, case 4 |
| Glu122Lys      | Infantile spasms, controlled | No | Non-verbal, gross motor delay | Yes | Yes | Head circumference <2nd centile at 5 years, unsteady gait | Nakajima et al. 2015 |
| Glu122Lys      | Infantile spasms, controlled | Yes | Yes | Yes | Yes | Small head circumference at birth, cerebral atrophy, ataxic gait | Nakajima et al. 2015 |
| Glu124Lys      | Myoclonic seizures from 3 months Absences from 2 years, controlled | No | Significant delays in language but speaks in sentences | No | No | Head circumference 25th centile at 5 years, gait immature but essentially normal | This study, case 6 |
| Asp252His      | Generalized tonic seizures, controlled | Yes | Yes | Yes | Yes | Small head circumference at birth, cerebral atrophy | Nakajima et al. 2015 |
| Arg423Cys      | Multiple daily seizures, intractable | NR | Global developmental delay | Yes | Yes | Head circumference 25th centile at 4 years, multiple food allergies | This study, case 7 |

1 Categorised under “Patients with Neurologic Plus Other Organ System Disease Phenotype” in Yang et al.

### Discussion

We have identified a series of further novel de novo missense mutations in EEF1A2 in patients with epilepsy, and thus build on the recently expanding evidence implicating EEF1A2 as a key player in a subset of related neurological syndromes.

None of the mutations is seen in the Exome Aggregation Consortium (ExAc) database that contains data from over 60,000 individuals. Indeed, EEF1A2 has been identified as one of the top thousand genes in the human genome considered to be subject to excessive constraint (Samocha et al. 2014); there are no known coding
polymorphisms. It is also noteworthy that a splice site mutation in EEF1B2 that encodes eEF1Bα, the GTP exchange factor for eEF1A, was detected in a consanguineous family with nonsyndromic intellectual disability (Najmabadi et al. 2011), highlighting the importance of this pathway for cognitive and neurological disorders.

All the mutations we identified are likely to impact on the structure or function of the protein according to either PolyPhen, SIFT analysis, or both. With the exception of R423C, all mutations in eEF1A2 are solvent accessible and located at or adjacent to known binding sites from yeast or rabbit structural or mutagenesis data. The R423C mutation is buried at the interdomain junction of the protein and is thus likely to have consequences for the protein structure or conformation.

The two cases with E122K mutations may suggest a possible mechanism by which mutations in EEF1A2 cause neuronal dysfunction, as the equivalent mutation in yeast was serendipitously characterized many years ago, and found to result in translational infidelity (Sandbaken and Culbertson 1988). The two children with E122K mutations both have an ataxia gait; ataxia has also been seen in individuals with mutations in genes encoding other proteins that are involved in the control of translational

![Case 1: c.208G>A (p.G70S)](image1)
![Case 3: c.271G>A (p.D91N)](image2)
![Case 4: c.292T>C (p.F98L)](image3)
![Case 5: c.364G>A (p.E122K)](image4)
![Case 7: c.1267 C>T (p.R423C)](image5)

**Figure 1.** Facial dysmorphologies in five of the cases reported in this study.

**Table 2.** Dysmorphological facial features seen in individuals with mutations in EEF1A2.

<table>
<thead>
<tr>
<th>Feature</th>
<th>Patient 1</th>
<th>Patient 2</th>
<th>Case 1</th>
<th>Case 3</th>
<th>Case 4</th>
<th>Case 5</th>
<th>Case 6</th>
<th>Case 7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deep set eyes</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>Epicanthus</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Depressed nasal bridge</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>Broad nasal bridge</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Tented upper lip</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>n.a.</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>High palate</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Everted lower lip</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Downturned corners of mouth</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

n.a., not able to be assessed.
fidelity, including a missense mutation in eEF2 that underlies spinocerebellar ataxia SCA26 (Hekman et al. 2012). In addition, a mutation in an editing-defective form of alanyl tRNA synthetase causes ataxia and neurodegeneration in mouse (Lee et al. 2006), and mutations in the gene encoding glutamine tRNA synthetase cause microcephaly and intractable epilepsy (Zhang et al. 2014). Whether similar molecular defects are seen in neurons of the child concerned having coped in mainstream school (case 6) it clearly has the least severe clinical effect, with no apparent physiological defects (Griffiths et al. 2012) because they are incompatible with life, the fact that mice never been detected in humans. While this could be suggested by Nakajima et al. (2015) to be part of a new “EEF1A2 syndrome” would necessarily apply in all cases, or be mutation dependent, or even a chance finding. Certainly of our seven patients, in only three cases were there any dysmorphisms noted. Following a careful review of all the photographs in cases for which we could obtain images, we conclude that indeed, there are subtle but characteristic features in common between all the individuals except case 6 (the child with the otherwise mild phenotype). The features seen in the cases we describe are consistent with those described by Nakajima et al., and include a broad nasal bridge, a tented upper lip and an everted lower lip associated with downturned corners of the mouth. It would be interesting to establish in humans the timing of the switch between eEF1A1 and eEF1A2 that occurs at ~3 weeks in rodents, and relate this to craniofacial development.

Autism has been reported in some individuals but not others. Until more cases are discovered, so that we can study more individuals with a specific given mutation, it will be impossible to judge whether a finding of autism is mutation dependent, or whether in fact individual stochastic differences are more significant than which amino acid has been mutated. Furthermore, patients with more severe intellectual disability may not meet the criteria for a diagnosis of autism.

The key question that remains is whether these mutations represent loss of function, or gain of function/dominant negative. No nonsense mutations or deletions have ever been detected in humans. While this could be because they are incompatible with life, the fact that mice with a heterozygous null mutation survive normally with no apparent physiological defects (Griffiths et al. 2012) might suggest that loss of function mutations in humans

<table>
<thead>
<tr>
<th>Protein change</th>
<th>DNA change</th>
<th>No. cases</th>
<th>PolyPhen-2 prediction; HumDiv/HumVar score (Benigo 0 to Probably Damaging 1)</th>
<th>SIFT prediction; Probabilities &lt;0.05 are predicted to be deleterious</th>
<th>Location with respect to known binding sites, or functional data</th>
</tr>
</thead>
<tbody>
<tr>
<td>G70S¹</td>
<td>G208A</td>
<td>3</td>
<td>Probably damaging; 0.998/0.980</td>
<td>Affect protein function; 0.00</td>
<td>Close to eEF1B binding site</td>
</tr>
<tr>
<td>I71L¹</td>
<td>A211C</td>
<td>1</td>
<td>Possibly damaging; 0.864/0.995</td>
<td>Affect protein function; 0.00</td>
<td>Close to eEF1B binding site</td>
</tr>
<tr>
<td>D91N¹</td>
<td>G277A</td>
<td>1</td>
<td>Probably damaging; 1.000/0.978</td>
<td>Affect protein function; 0.00</td>
<td>Overlaps eEF1B binding site</td>
</tr>
<tr>
<td>F98L¹</td>
<td>T292C</td>
<td>1</td>
<td>Benign; 0.138/0.145</td>
<td>Affect protein function; 0.00</td>
<td>Overlaps eEF1B binding site</td>
</tr>
<tr>
<td>E122K¹</td>
<td>G364A</td>
<td>2</td>
<td>Probably damaging; 1.000/0.999</td>
<td>Tolerated; 0.16</td>
<td>Affects translational fidelity in yeast; close to GTP/GDP-binding site</td>
</tr>
<tr>
<td>E124K¹</td>
<td>G370A</td>
<td>1</td>
<td>Benign; 0.101/0.072</td>
<td>Affect protein function; 0.03</td>
<td>No direct overlap with known binding sites but close to GTP/GDP-binding site</td>
</tr>
<tr>
<td>D252H</td>
<td>G754C</td>
<td>1</td>
<td>Probably damaging; 0.962/0.980</td>
<td>Affect protein function; 0.00</td>
<td>Overlaps eEF1B binding site</td>
</tr>
<tr>
<td>R423C¹</td>
<td>C1267T</td>
<td>1</td>
<td>Benign; 0.054/0.092</td>
<td>Affect protein function; 0.00</td>
<td>Buried</td>
</tr>
</tbody>
</table>

¹Reported in this study, in bold = reported for the first time.

²Based upon experimental structural and/or functional data of equivalent amino acid residue in yeast eEF1A (Sandbaken and Culbertson 1988; Andersen et al. 2001; Soares et al. 2009; Crepin et al. 2014).
have not been detected because they do not give rise to overt disorders. However, the lack of polymorphisms in *EEF1A2* would argue against this explanation, so perhaps loss of function is simply better tolerated in mice, at least in terms of seizures and muscle function (since grip strength in heterozygous null mice is unaffected right up to 21 months, the oldest age of testing). This might suggest that the missense mutations in humans cause a gain

![Figure 2. Evolutionary conservation of amino acids mutated in *EEF1A2* in individuals with epilepsy.](image-url)

| Human 1A2 | -----MGKEKTHINVIGHVDSGKTTTHTGLHYYKCIKGDIRKTEIFKE2EAEMNGKSFK |
| Mouse 1A2 | -----MGKEKTHINVIGHVDSGKTTTHTGLHYYKCIKGDIRKTEIFKE2EAEMNGKSFK |
| Human 1A1 | -----MGKEKTHINVIGHVDSGKTTTHTGLHYYKCIKGDIRKTEIFKE2EAEMNGKSFK |
| Yeast 1A | -----MGKEKSHINVIGHVDSGKTTTHTGLHYYKCIKGDIRKTEIFKE2AELLGKSFK |
| *E. coli* EF-Tu | MSKEKFTERTKPHVNGVTGUYHDKGTLTAAITTLVAKT-------------Y-GGAAR |

| Human 1A2 | YAWVLDLKLKEREGITIDLSLWKETKYYITIIDAPGHRDFIKNMITGTSQACAVLI |
| Mouse 1A2 | YAWVLDLKLKEREGITIDLSLWKETKYYITIIDAPGHRDFIKNMITGTSQACAVLI |
| Human 1A1 | YAWVLDLKLKEREGITIDLSLWKETKYYITIIDAPGHRDFIKNMITGTSQACAVLI |
| Yeast 1A | YAWVLDLKLKEREGITIDLSLWKETKYYITIIDAPGHRDFIKNMITGTSQACAVLI |
| *E. coli* EF-Tu | AFDQIDNAEERKARGINTSHVEYTDPRTYHVADCPHADTVKNMITGAAQMDAILV |

| Human 1A2 | VAAGVGEFAGIKNGQTTREHALLAYTLGKQLIGTVGNMKDSTEPAYSEKRDEIVKEVS |
| Mouse 1A2 | VAAGVGEFAGIKNGQTTREHALLAYTLGKQLIGTVGNMKDSTEPAYSEKRDEIVKEVS |
| Human 1A1 | VAAGVGEFAGIKNGQTTREHALLAYTLGKQLIGTVGNMKDSTEPAYSEKRDEIVKEVS |
| Yeast 1A | VAAFGVGEFAGIKNGQTTREHALLAYTLGKQLIGTVGNMKDSTEPAYSEKRDEIVKEVS |
| *E. coli* EF-Tu | VAAAGFM--------PTREHILLGRQVFGYVIFVPLNKCMDVDEE----LELLEEMEVR |

| Human 1A2 | AYIKKIGYNPATVFVPFVSPISWHGDNMLEPSNMPF6KVGKVERKENGASGVISLLEAL-T |
| Mouse 1A2 | AYIKKIGYNPATVFVPFVSPISWHGDNMLEPSNMPF6KVGKVERKENGASGVISLLEAL-T |
| Human 1A1 | TYIKKIGYNPDTVFVPISWHGDNMLEPSNAMFGKVGKVERKENGASGVISLLEAL-T |
| Yeast 1A | NPIKKGYNF6KTFVFVPISWHGDNMIABATNPWYKGEKVKVGKTLLEAL-A |
| *E. coli* EF-Tu | ELLSKYDFPGDTPVIRGSA-----------DKAGLEDAE--------WEAKI----------LELAQFLDSY |

| Human 1A2 | ILPTRPTRLKRLPLQDYIKGIGITVPGVQRVETGLRPVGMVFAPVNT---TEVKS |
| Mouse 1A2 | ILPTRPTRLKRLPLQDYIKGIGITVPGVQRVETGLRPVGMVFAPVNT---TEVKS |
| Human 1A1 | ILPTRPTRLKRLPLQDYIKGIGITVPGVQRVETGLRPVGMVFAPVNT---TEVKS |
| Yeast 1A | IEQPSFRTPDPLRLPQDYIKGIGITVPGVQRVETGLRPVGMVFAPVNT---TEVKS |
| *E. coli* EF-Tu | IPEPERAIDKPLLPIEDVFSISRGRSTVGTGRVIEIKYEVEIEVGKETQKSTCTGV |

| Human 1A2 | EMHHEALSEAPDNVGNFKTVNKSVKDIRGRNGVGSKSDPQEAAQFTSVQIVIHNHPG- |
| Mouse 1A2 | EMHHEALSEAPDNVGNFKTVNKSVKDIRGRNGVGSKSDPQEAAQFTSVQIVIHNHPG- |
| Human 1A2 | EMHHEALSEAPDNVGNFKTVNKSVKDIRGRNGVGSKSDPQEAAQFTSVQIVIHNHPG- |
| Yeast 1A | EMHHEQLEGQVFVDGNVKNVNFVKIVRGERQNGCDKNDPPFPGKACSNFATVIVLHNPG- |
| *E. coli* EF-Tu | EFRKILLEDGAGENYVQILRLIERGQVIVAKPTKIRH---TFKSEVEYILSKDEG |

| Human 1A2 | -----QISAGYSPVLDCTHAHIACKFAELKEKIDRRSGKLEKDNPQSLKASDDAIMEVMPG |
| Mouse 1A2 | -----QISAGYSPVLDCTHAHIACKFAELKEKIDRRSGKLEKDNPQSLKASDDAIMEVMPG |
| Human 1A1 | -----QISAGYSPVLDCTHAHIACKFAELKEKIDRRSGKLEKDNPQSLKASDDAIMEVMPG |
| Yeast 1A | -----QISAGYSPVLDCTHAHIACKFAELKEKIDRRSGKLEKDNPQSLKASDDAIMEVMPG |
| *E. coli* EF-Tu | GRHTPFVKGRQFQYRTFDDVGT---------IE--------LPEGVMVMPFDNQMVTL |

| Human 1A2 | KPMCVEFESFSQPYPLGFARVRMDRQTAVVGVKNVEKSKGAGKVKSAQQKQAKG |
| Mouse 1A2 | KPMCVEFESFSQPYPLGFARVRMDRQTAVVGVKNVEKSKGAGKVKSAQQKQAKG |
| Human 1A1 | KPMCVEFESFSQPYPLGFARVRMDRQTAVVGVKNVEKSKGAGKVKSAQQKQAKG- |
| Yeast 1A | KPMCVEFESFSQPYPLGFARVRMDRQTAVVGVKNVEKSKGAGKVKSAQQKQAKG- |
| *E. coli* EF-Tu | HPIAM-------DDGLRFAIREGGRVAGVVAKVLG--------------
of function, or dominant negative effect – further cases, or study of the mutations in animal models, will be needed to resolve these issues.

Acknowledgments
We thank the patients and their families for their participation and support of this study, and for helpful discussion. The Deciphering Developmental Disorders study presents independent research commissioned by the Health Innovation Challenge Fund (grant number HICF-1099-003), a parallel funding partnership between the Wellcome Trust and the Department of Health, and the Wellcome Trust Sanger Institute (grant number WT098051). The views expressed in this publication are those of the author(s) and not necessarily those of the Wellcome Trust or the Department of Health. The study has UK Research Ethics Committee approval (10/H0305/83, granted by the Cambridge South REC, and GEN/284/12 granted by the Republic of Ireland REC). The research team acknowledges the support of the National Institute for Health Research, through the Comprehensive Clinical Research Network.

Conflict of Interest
None declared.

References


